[
  {
    "ticker": "IFT",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968812",
    "id": "02968812",
    "pages": 2,
    "price_sensitive": false,
    "date": "20250714",
    "time": "0750",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrlpl4zvvyw0.pdf",
    "summary": "<ul>\n<li><strong>Director Share Acquisition</strong>: Jason Boyes (CEO &amp; Director) increased holdings in Infratil Limited (IFT) via on-market purchases.  </li>\n<li><strong>Transaction Details</strong>:  </li>\n<li><strong>7-Jul-25</strong>: 22,900 shares @ NZ$10.9542/share (total ~NZ$250,851).  </li>\n<li><strong>8-Jul-25</strong>: 22,250 shares @ NZ$10.9584/share (total ~NZ$243,824).  </li>\n<li><strong>11-Jul-25</strong>: 243 shares @ NZ$10.92251/share (total ~NZ$2,654).  </li>\n<li><strong>Total Shares Held</strong>: Increased from 2,382,437 to 2,427,830.  </li>\n</ul>\n<p><em>No material impact on capital structure or liquidity; reflects insider bullish sentiment.</em></p>",
    "usage": {
      "prompt_tokens": 947,
      "completion_tokens": 169,
      "total_tokens": 1116,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-13T21:55:49.309907"
  },
  {
    "ticker": "PEB",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968811",
    "id": "02968811",
    "pages": 10,
    "price_sensitive": true,
    "date": "20250714",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrlhgrd1s0s7.pdf",
    "summary": "<h3><strong>Key Material Information Extracted:</strong></h3>\n<h4><strong>Capital Raising:</strong></h4>\n<ul>\n<li><strong>Structure:</strong> Placement + Share Purchase Plan (SPP)  </li>\n<li><strong>Placement Amount:</strong> AUD $16.1M (oversubscribed, initial target $15M)  </li>\n<li><strong>SPP Amount:</strong> AUD $5M (with potential oversubscriptions)  </li>\n<li><strong>Price:</strong> AUD $0.10/share (18% premium to 20-day VWAP)  </li>\n<li><strong>Key Dates:</strong>  </li>\n<li><strong>Annual Meeting (for approval):</strong> 6 Aug 2025  </li>\n<li><strong>SPP Expected Open:</strong> Mid-July 2025 (conditional on placement approval)  </li>\n</ul>\n<h4><strong>Operational/Financial Highlights (Q1 2025):</strong></h4>\n<ul>\n<li><strong>US Test Volumes (TLT):</strong> Down 11.9% QoQ to 5,717 tests (due to transition from <em>Detect</em> to <em>Triage</em>).  </li>\n<li><strong>APAC Test Volumes:</strong> Up 8.8% QoQ to 1,183 tests.  </li>\n<li><strong>Triage Adoption:</strong> 77% of US tests in June 2025 (vs. 22% in Q4 2024).  </li>\n</ul>\n<h4><strong>Medicare Coverage Update:</strong></h4>\n<ul>\n<li><strong>Reconsideration Request Submitted:</strong> Based on new evidence (STRATA study + AUA guideline inclusion).  </li>\n<li><strong>Novitas Engagement:</strong> Positive initial discussions; potential reopening of LCD (Local Coverage Determination).  </li>\n<li><strong>Triage Plus:</strong>  </li>\n<li>Draft Medicare price: <strong>US$1,018/test</strong> (vs. $760 for <em>Triage</em>).  </li>\n<li>Analytical validation published; clinical validation (DRIVE study) under peer review.  </li>\n</ul>\n<h4><strong>Contract Wins/Payer Progress:</strong></h4>\n<ul>\n<li><strong>Optum VACCN:</strong> Secured \"in-network\" status (pays Medicare rates for veterans\u2019 tests).  </li>\n<li><strong>BCBS GPO:</strong> Contracting win; ongoing negotiations with other payers.  </li>\n</ul>\n<hr />\n<p><strong>Note:</strong> Omitted non-material details (e.g., director re-elections, meeting logistics). Prioritized liquidity, valuation, and capital structure impacts.</p>",
    "usage": {
      "prompt_tokens": 7214,
      "completion_tokens": 442,
      "total_tokens": 7656,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-13T21:56:05.633136"
  },
  {
    "ticker": "SNZ",
    "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968810",
    "id": "02968810",
    "pages": 6,
    "price_sensitive": false,
    "date": "20250714",
    "time": "0730",
    "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06lrlf7nq5f4mq.pdf",
    "summary": "<h3><strong>Summary of ASX Announcement \u2013 Appendix 2A (Application for Quotation of Securities)</strong></h3>\n<ul>\n<li><strong>Security Issuance under Employee Incentive Scheme</strong>  </li>\n<li><strong>Total securities issued:</strong> 192,360 ordinary shares (SNZ)  </li>\n<li><strong>Issue date:</strong> 14/07/2025  </li>\n<li><strong>Issue price:</strong> NZD 11.8757 per share (~AUD equivalent not provided)  </li>\n<li><strong>Ranking:</strong> Equal to existing ordinary shares  </li>\n<li>\n<p><strong>Recipients include KMP:</strong>  </p>\n<ul>\n<li>Scott Scoullar \u2013 84 shares  </li>\n<li>Margaret Warrington \u2013 84 shares  </li>\n</ul>\n</li>\n<li>\n<p><strong>Impact on Issued Capital</strong>  </p>\n</li>\n<li><strong>Total ordinary shares on issue post-quotation:</strong> 241,123,378  </li>\n</ul>\n<p><strong>Note:</strong> No material trading or capital markets impact identified (small issuance under incentive scheme with minimal dilution).</p>",
    "usage": {
      "prompt_tokens": 1489,
      "completion_tokens": 185,
      "total_tokens": 1674,
      "prompt_tokens_details": null
    },
    "model": "deepseek/deepseek-chat-v3-0324:free",
    "processed_at": "2025-07-13T21:55:55.174542"
  }
]